1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Medivation Inc. (MDVN) President and CEO David Hung sells 25,000 Shares

December 08, 2009 | About:

President and CEO of Medivation Inc. (NASDAQ:MDVN) David Hung sells 25,000 shares of MDVN on 12/07/2009 at an average price of $33.27 a share.

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. The Company had built a portfolio of innovative medical technologies and a team of employees and seasoned consultants with significant expertise in the identification, evaluation, acquisition, development and sale/partnering of small molecule therapeutics, biotechnology products and medical devices Medivation Inc. has a market cap of $1.11 billion; its shares were traded at around $33.25 with and P/S ratio of 88.6.

MDVN is in the portfolios of George Soros of Soros Fund Management LLC.

Insiders' Positions with MDVN



  • Sell:: President and CEO David Hung sold 25,000 shares of MDVN stock on 09/10/2009 at the average price of 25.84, the price of the stock has increased by 28.68% since
  • Sell:: President and CEO David Hung sold 25,000 shares of MDVN stock on 07/01/2009 at the average price of 22.62, the price of the stock has increased by 46.99% since


Insiders' Positions with MDVN



  • Sell:: Sr. Vice President and CFO Clarence Patrick Machado sold 20,000 shares of MDVN stock on 11/11/2009 at the average price of 28.28, the price of the stock has increased by 17.57% since
  • Sell:: Sr. Vice President and CFO Clarence Patrick Machado sold 20,000 shares of MDVN stock on 09/10/2009 at the average price of 25.86, the price of the stock has increased by 28.58% since
  • Sell:: Sr. Vice President and CFO Clarence Patrick Machado sold 20,000 shares of MDVN stock on 07/01/2009 at the average price of 22.48, the price of the stock has increased by 47.91% since


Insiders' Positions with MDVN



  • Sell:: Director Gregory Bailey sold 10,000 shares of MDVN stock on 12/01/2009 at the average price of 31.49, the price of the stock has increased by 5.59% since
  • Sell:: Director Gregory Bailey sold 14,000 shares of MDVN stock on 11/20/2009 at the average price of 25.99, the price of the stock has increased by 27.93% since
  • Sell:: Director Gregory Bailey sold 14,000 shares of MDVN stock on 11/20/2009 at the average price of 29, the price of the stock has increased by 14.66% since
  • Sell:: Director Gregory Bailey sold 10,000 shares of MDVN stock on 09/14/2009 at the average price of 25.99, the price of the stock has increased by 27.93% since
  • Sell:: Chief Medical Officer Lynn Seely sold 18,000 shares of MDVN stock on 09/10/2009 at the average price of 25.87, the price of the stock has increased by 28.53% since


  • CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
  • Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
  • Double Buys:: Companies that both Gurus and Insiders are buying
  • Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.

» Take a Free Trial of Premium Membership

About the author:

insider
GuruFocus - Stock Picks and Market Insight of Gurus

Rating: 3.5/5 (4 votes)

Comments

Please leave your comment:


Select portfolio(s):

  • Loading...

Why you are interested?

Your selection and notes will be stored in your portfolio.

Login to add portfolio
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK